399037-37-7

Basic information

• Product Name: 1-Piperazinecarboxamide, N-[4-(1-methylethoxy)phenyl]-, hydrochloride
• Synonyms: 1-Piperazinecarboxamide, N-[4-(1-methylethoxy)phenyl]-, hydrochloride
• CAS NO: 399037-37-7
• Molecular Formula: C₁₄H₂₁N₃O₂*ClH
• Molecular Weight: 299.79638
• Mol File: 399037-37-7.mol

Chemical Properties

• Appearance: /
• CAS DataBase Reference: 1-Piperazinecarboxamide, N-[4-(1-methylethoxy)phenyl]-, hydrochloride(CAS DataBase Reference)
• NIST Chemistry Reference: 1-Piperazinecarboxamide, N-[4-(1-methylethoxy)phenyl]-, hydrochloride(399037-37-7)
• EPA Substance Registry System: 1-Piperazinecarboxamide, N-[4-(1-methylethoxy)phenyl]-, hydrochloride(399037-37-7)

Safety Data

• Hazardous Substances Data: 399037-37-7(Hazardous Substances Data)

Upstream product

• 110-85-0 piperazine 
• 450390-76-8 phenyl (4-isopropoxyphenyl)carbamate 

Downstream Products

• 460088-36-2 4-{4-(4-Isopropoxy-phenylcarbamoyl)-piperazin-1-yl]-6-methoxy-7-(3-piperidin-1-yl-propoxy)-quinolin-3-carboxylic Acid Ethyl Ester 
• 387867-13-2 Tandutinib 

Relevant articles and documents

LACTATE SALT OF 4-[6-METHOXY-7-(3-PIPERIDIN-1-YL-PROPOXY)QUINAZOLIN-4-YL]PIPERAZINE-1-CARBOXYLIC ACID(4-ISOPROPOXYPHENYL)-AMIDE AND PHARMACEUTICAL COMPOSITIONS THEREOF FOR THE TREATMENT OF CANCER AND OTHER DISEASES OR DISORDERS

This invention provides a compound of formula (I): or a crystalline form thereof, or a pharmaceutical composition thereof, or an oral pharmaceutical dosage form thereof; processes for the synthesis or manufacture of the compound of formula (I), or a cryst

LACTATE SALT OF 4-(6-METHOXY-7-(3-PIPERIDIN-1-YL-PROPOXY)QUINAZOLIN-4-YL]PIPERAZINE-1-CARBOXYLIC ACID(4-ISOPROPOXYPHENYL)-AMIDE AND PHARMACEUTICAL COMPOSITIONS THEREOF FOR THE TREATMENT OF CANCER AND OTHER DISEASES OR DISORDERS

This invention provides a compound of formula (I): or a crystalline form thereof, or a pharmaceutical composition thereof, or an oral pharmaceutical dosage form thereof; processes for the synthesis or manufacture of the compound of formula (I), or a crystalline form thereof, or a pharmaceutical composition thereof, or an oral pharmaceutical dosage form thereof; and the use of said compound, or a crystalline form thereof, or a pharmaceutical composition thereof, or an oral pharmaceutical dosage form thererof, for the treatment of patients suffering from or subject to diseases, disorders or conditions involving cell survival, proliferation, and migration, including cardiovascular disease (e.g., arteriosclerosis and vascular reobstruction), cancer, (e.g., AML and malignant glioma) glomerulosclerosis, fibrotic disease and inflammation.